Therapeutic oligonucleotides: The road not taken

Clinical Cancer Research

Volumn 17, Issue 20, 2011, Pages 6369-6372

  Stein, Cy A ^a   Goel, Sanjay ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DACARBAZINE; LY 2275796; OBLIMERSEN; PROTEIN BCL 2; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CHEMICAL MODIFICATION; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE SILENCING; GENE TARGETING; HUMAN; IN VIVO STUDY; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; UNITED STATES;

ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; TRANSCRIPTION FACTORS;

EID: 80054094688     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2013     Document Type: Article

References (11)

1. Hong DS, Kurzrock R, Oh Y, Wheler JJ, Naing A, Brail L, et al. A phase 1 dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of eif-4e antisense oligonucleotide ly2275796 in patients with advanced cancer. Clin Cancer Res 2011;17: 6582-91.
2. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007;117:2638-48. (Pubitemid 47494364)
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
4. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45. (Pubitemid 46630937)
5. Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 1988;16:3209-21.
6. Gekeler V, Gimmnich P, Hofmann H-P, Grebe C, Römmele M, Leja A, et al. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 2006;16:83-93.
7. Benimetskaya L, Lai JC, Khvorova A, Wu S, Hua E, Miller P, et al. Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Clin Cancer Res 2004;10: 8371-9. (Pubitemid 40053399)
8. Smalley K, Haass M, Brafford P, Lioni M, Flaherty KT, Herlyn M, et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-44. (Pubitemid 43881305)
9. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, et al. Chemosensitisation of malignant melanoma by BCL2 antisensetherapy. Lancet 2000;356: 1728-33.
10. Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, et al. LDH correlation with survival in advanced melanoma from twolarge, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009;45:1807-14.
11. Stein CA, Hansen B, Lai J, Wu S, Voskresenskiy A, Høg A, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfecton reagents. Nucleic Acids Res 2010;38:e3.